ReviewNeuroscience bulletin2017
Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?
Review in Neuroscience bulletin, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Connectivity and Functionality of the Globus Pallidus Externa Under Normal Conditions and Parkinson's Disease.Frontiers in neural circuits · 2021Pooled it
- Assessing White Matter Pathology in Early-Stage Parkinson Disease Using Diffusion MRI: A Systematic Review.Frontiers in neurology · 2020Pooled it
- Effect of α-Synuclein Overexpression on NAPP-129 and TLQP-62 in Rat Brain and Plasma.Medical sciences (Basel, Switzerland) · 2026Article
- Behavior- and Cell Type-Specific Cortico-Striatal Decoupling in a Parkinson's Disease-Like Mouse Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Multi-omics machine learning classifier and blood transcriptomic signature of Parkinson's disease.Research square · 2025Article
- Parkinson biomarker determination with an Au microflower-enhanced electrochemical immunosensor using non-Faradaic capacitance measurements.Mikrochimica acta · 2024Article
- From small to tall: breed-varied household pet dogs can be trained to detect Parkinson's Disease.Animal cognition · 2024Article
- Transcriptional pathobiology and multi-omics predictors for Parkinson's disease.bioRxiv : the preprint server for biology · 2024Article
- From the Gut to the Brain: Is Microbiota a New Paradigm in Parkinson's Disease Treatment?Cells · 2024Review
- An innovative transportable immune device for the recognition of α-synuclein using KCC-1-RSC advances · 2024Article
- A Comprehensive Review of the Role of Biomarkers in Early Diagnosis of Parkinson's Disease.Cureus · 2024Review
- Biomarkers: Role and Scope in Neurological Disorders.Neurochemical research · 2023Review
- NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson's Disease.Neuroscience bulletin · 2023Review
- Searching for Biomarkers in the Blood of Patients at Risk of Developing Parkinson's Disease at the Prodromal Stage.International journal of molecular sciences · 2023Article
- Salivary Biomarkers: Noninvasive Ways for Diagnosis of Parkinson's Disease.Neurology research international · 2023Review
- Analysis ofBioMed research international · 2023Article
- Modulation of Small RNA Signatures by Astrocytes on Early Neurodegeneration Stages; Implications for Biomarker Discovery.Life (Basel, Switzerland) · 2022Review
- Stacked Model-Based Classification of Parkinson's Disease Patients Using Imaging Biomarker Data.Biosensors · 2022Article
- Proton Magnetic Resonance Spectroscopy for Diagnosis of Non-Motor Symptoms in Parkinson's Disease.Frontiers in neurology · 2022Article
- Mitochondrial Defects in Fibroblasts of PathogenicFrontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a complex neurodegenerative disease with progressive loss of dopamine neurons. PD patients usually manifest a series of motor and non-motor symptoms. In order to provide better early diagnosis and subsequent disease-modifying therapies for PD patients, there is an urgent need to identify sensitive and specific biomarkers. Biomarkers can be divided into four categories: clinical, imaging, biochemical, and genetic. Ideal biomarkers not only improve our understanding of PD pathogenesis and progression, but also provide benefits for early risk evaluation and clinical diagnosis of PD. Although many efforts have been made and several biomarkers have been extensively investigated, few if any have been found useful for early diagnosis. Here, we summarize recent developments in the discovered biomarkers of PD and discuss their merits and limitations for the early diagnosis of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.